Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cue Biopharma, Inc. (CUE : NSDQ)

• Company Description    Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $21.47 Daily Weekly Monthly 20 Day Moving Average: 1,403,194 shares Shares Outstanding: 4.05 (millions) Market Capitalization: $86.86 (millions) Beta: 2.37 52 Week High: $41.42 52 Week Low: $4.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 29.01% 22.70% 12 Week 148.33% 129.57% Year To Date 134.10% 101.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 GUEST STREET - BOSTON,MA 02135 USA ph: 617-949-2680 fax: - ir@cuebio.com http://www.cuebiopharma.com

• General Corporate Information    Officers Usman Azam - President; Chief Executive Officer and Director Lucinda Warren - Chief Financial and Business Officer Peter A. Kiener - Director Jill Marie Broadfoot - Director Pamela Garzone - Director Peer Information Cue Biopharma, Inc. (CORR.) Cue Biopharma, Inc. (RSPI) Cue Biopharma, Inc. (CGXP) Cue Biopharma, Inc. (BGEN) Cue Biopharma, Inc. (GTBP) Cue Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22978P205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 4.05 Most Recent Split Date: 4.00 (0.03:1) Beta: 2.37 Market Capitalization: $86.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.02 Price/Cash Flow: - Price / Sales: 2.65 EPS Growth vs. Year Ago Period: 78.84% vs. Previous Quarter: -459.64% Sales Growth vs. Year Ago Period: 1,250.59% vs. Previous Quarter: -74.09% ROE 03/31/26 - -98.30 12/31/25 - -165.19 09/30/25 - -271.67 ROA 03/31/26 - -53.69 12/31/25 - -77.77 09/30/25 - -118.88 Current Ratio 03/31/26 - 3.57 12/31/25 - 2.74 09/30/25 - 1.66 Quick Ratio 03/31/26 - 3.57 12/31/25 - 2.74 09/30/25 - 1.66 Operating Margin 03/31/26 - -59.65 12/31/25 - -96.85 09/30/25 - -530.75 Net Margin 03/31/26 - -59.65 12/31/25 - -96.85 09/30/25 - -530.75 Pre-Tax Margin 03/31/26 - -58.12 12/31/25 - -95.03 09/30/25 - -530.75 Book Value 03/31/26 - 5.34 12/31/25 - 10.08 09/30/25 - 5.18 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 1.41

Powered by Zacks Investment Research ©